Highlights

  • Emyria reported FY26 Revenue of approximately $4.3 million, up around 210% YoY.
  • The company operates five Empax clinics across four Australian states.
  • Early treatment-resistant depression data showed improvements across standard mental-health measures.
  • Emyria is expanding its clinic network with a planned New South Wales location.

Emyria (ASX:EMD) is a healthcare company focused on psychedelic-assisted therapy and mental-health services through its Empax clinic network. The company is developing a revenue-generating healthcare model by providing patient treatments while continuing to build clinical data and regulatory capabilities.

At the time of writing on 14 August 2026, Emyria (ASX:EMD) was trading at AUD 0.046, unchanged on the day.

The company’s latest update highlighted revenue growth, expansion of its clinic network and continued development of its mental-health treatment platform.

What Just Happened?

On 29 July 2026, Emyria reported FY26 revenue of approximately $4.3 million, representing growth of around 210% compared with the prior year.

Fourth-quarter revenue reached approximately $1.53 million, including around $191,000 from a Research and Development tax refund.

The company attributed growth to the expansion of its Empax clinic network, which provides psychedelic-assisted treatments and broader mental-health services.

Emyria reported that it operates five Empax clinics across four states. During FY26, the company expanded operations with a Victorian clinic on the Mornington Peninsula and planned a New South Wales clinic at Matilda Nepean Private Hospital for the September quarter.

The company also highlighted early clinical data from a 10-patient treatment-resistant depression cohort, where average depression scores improved from 16.8 to 10.0, representing a 6.8-point reduction.

Emyria’s clinic network is supported by more than 100 contracted and trained psychiatrists and therapists.

Why It Matters

The increase in revenue demonstrates progress in converting psychedelic-assisted therapy from a developing healthcare concept into a patient service model generating commercial activity.

Australia’s regulatory framework allows authorised prescribers to use MDMA and psilocybin for specific conditions under controlled requirements, creating a pathway for companies such as Emyria to establish treatment networks.

The early clinical data provides additional information on patient outcomes, although the results are based on a small cohort and require further validation across larger patient groups.

Regulatory developments may also influence future expansion. In May 2026, Emyria highlighted potential changes that could broaden the range of healthcare professionals involved in psychedelic-assisted psychotherapy, which may support future clinic capacity.

The Bigger Picture

Emyria is a Western Australia-based healthcare company combining clinical services with Drug Development activities.

The Empax clinic network is the company’s primary commercial operation, providing psychedelic-assisted therapy and other mental-health treatments for conditions including treatment-resistant depression and post-traumatic stress disorder.

Unlike biotechnology companies that rely entirely on future clinical trial outcomes, Emyria generates revenue through direct patient services while collecting treatment data that may support future clinical and regulatory activities.

The company operates within two highly regulated areas: controlled medicine treatments and healthcare service delivery. Scaling the model requires trained clinicians, operational systems, referral networks and ongoing regulatory compliance.

Emyria’s longer-term strategy involves building a broader evidence-based mental-health platform while maintaining potential drug-development opportunities.

What Could Drive the Shares Next?

The opening of the planned New South Wales Empax clinic is a key upcoming milestone for Emyria. Expanding into New South Wales would increase the company’s geographic footprint and treatment capacity.

Investors will also monitor Quarterly Revenue Growth to assess whether the clinic network can continue scaling.

Further clinical outcomes from patient treatment programs may provide additional information on treatment effectiveness and support future adoption.

The implementation of broader prescriber eligibility under the Therapeutic Goods Administration framework may also influence staffing capacity and clinic expansion.

Funding developments and progress toward sustainable cash generation will remain important as the company continues investing in its network.

Risks Investors Should Watch

Emyria faces risks related to funding, regulation, clinical outcomes and operational execution. Expanding specialist healthcare clinics requires ongoing Investment in facilities, staffing and compliance, and the company may require additional Capital as it grows. Psychedelic-assisted therapy remains subject to strict regulatory controls, and changes to clinical guidelines, reimbursement arrangements or treatment requirements could affect demand. Early clinical results from small patient groups may not be replicated at larger scale. Additional risks include competition, healthcare delivery challenges and Volatility associated with smaller ASX-listed healthcare companies.

Bottom Line

Emyria (ASX:EMD) is progressing from an early-stage psychedelic healthcare concept toward a revenue-generating clinical services business, supported by FY26 revenue growth and expansion of its Empax clinic network.

The company has established operations across multiple Australian states and is building clinical data alongside commercial activity.

The next stage will depend on continued revenue growth, successful clinic expansion, regulatory developments and the ability to manage funding requirements while scaling the business.

Emyria provides exposure to an emerging healthcare sector, but remains a small-cap company operating within a developing and highly regulated treatment environment.